Dr. Fischer has 25 years experience from the biotech and pharmaceutical industry within product development and business development. He has founded and run several biotech companies, worked as a biotech consultant and been an entrepreneur in residence with Novo Holdings. Primary therapeutic areas have been immunology, vaccines, haemostasis and oncology. Per holds a D.Phil. from University of Oxford and has 6 years of laboratory experience within immunology and infectious diseases prior to starting his industrial career.
Lidia has more than 25 years’ R&D experience, with focus on clinical development, both in pharmaceutical companies as in biotech. She spent more than 20 years of her industry career in development of prophylactic vaccines and has led several large phase 3 clinical programs. She holds a Medical Degree from the University of Ghent (Belgium) and is specialized in Pharmaceutical Medicine.
Anders Vadsholt, CFO
Anders has more than 25 years’ experience from corporate finance, venture capital and the biotech industry. He has recently been CEO and CFO of Orphazyme A/S, which he took public on NASDAQ Copenhagen and NASDAQ New York. Previous experience from Topotarget A/S, BankInvest Biomedical Venture, and Carnegie Investment Bank. Anders holds an MSc in Commercial Law and Economics from Copenhagen Business School and a MBA from Melbourne University.
Bengt Johansson Lindbom,
Dr. Johansson Lindbom holds a PhD in Immunotechnology from Lund University. He has 15 years of experience from heading research groups at Lund University and at Denmark Technical University (DTU), and has been the main supervisor for several completed PhD and post-doctoral projects. His research has focused on adaptive immune responses in settings of vaccination and infections, with specific interests in dendritic cell biology, B cell-mediated immunity and protective immunological memory. He was the coordinator of the EU FP7 funded project NeoStrep and, since the start of this vaccine research programme, he has continued to work in close collaboration with MinervaX on the maternal Group B streptococcus vaccine. In parallel to his current assignment as the CSO of MinervaX, he is an Associate Professor at the section for immunology, Lund University. Dr. Johansson Lindbom is the author to a number of studies published in top-tiered international immunological journals, including the Journal of Experimental Medicine, the Journal of Immunology, Nature medicine and Immunity.
CTO, Head of CMC
Dr. Kantsø has +15 years experience within the field of bacterial vaccines. Dr. Kantsø received a M.Sc in Biotechnology from the Technincal University of Denmark and a Ph.D from Univiersity og Copenhagen. Dr. Kantsø joined MinervaX in 2021, and currently serves as Chief Technology Officer and Head of Chemistry Manufacturing and Controls (CMC). Prior to MinervaX, Dr. Kantsø was at Lundbeck, where he helped build the Biophamacutical Division. Prior to Lundbeck, Dr. Kantsø was head of a QC department at the CMO AGC Biologics (former CMC Biologics). Prior to AG Biologics Dr. Kantsø served as laboratory leader and assay development scientist at Statens Serum Institut.